靶向p16INK4a介导的细胞衰老作为FLT3-ITD驱动急性髓系白血病的治疗策略
研究通过多个测序数据集分析发现,FLT3-ITD阳性且p16INK4a低表达的患者预后显著更差;小鼠中敲除p16INK4a可加速FLT3-ITD急性髓系白血病发生。机制上,FLT3-ITD突变通过STAT5A-E2F3-EZH2信号轴抑制p16INK4a表达,使细胞逃避衰老并形成正反馈环路加剧疾病进展,该轴为低p16INK4a表达的难治性FLT3-ITD急性髓系白血病提供了有前景的治疗靶点。
要点
- FLT3-ITD阳性且p16INK4a低表达的患者预后显著更差
- 小鼠敲除p16INK4a可加速FLT3-ITD急性髓系白血病发生
- FLT3-ITD经STAT5A-E2F3-EZH2轴抑制p16INK4a,使细胞逃避衰老并促进恶性进展
核心结论
- FLT3-ITD突变通过STAT5A-E2F3-EZH2信号轴抑制p16INK4a表达,使细胞逃避衰老,促进恶性程度增加并形成正反馈环路加剧疾病进展。
- 该机制为FLT3-ITD阳性且p16INK4a低表达患者长期生存较差提供了分子解释。
- 本研究鉴定的FLT3-ITD-STAT5A/E2F3/EZH2-p16INK4a轴是应对低p16INK4a表达难治性FLT3-ITD急性髓系白血病的有前景治疗靶点。
研究设计与样本
- 研究分析多个测序数据集,并在小鼠中进行p16INK4a敲除实验。
主要发现
- FLT3-ITD阳性且p16INK4a低表达的患者预后显著更差。
- 小鼠中敲除p16INK4a可加速FLT3-ITD急性髓系白血病发生。
- FLT3-ITD突变通过STAT5A-E2F3-EZH2信号轴抑制p16INK4a表达。
- p16INK4a下调使细胞逃避衰老,促进恶性程度增加并形成正反馈环路加剧疾病进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cellular senescence serves as a critical tumor-suppressive mechanism across various cancer types, yet its role in FLT3-ITD-positive acute myeloid leukemia (AML) remains poorly understood. Through the analysis of multiple sequencing datasets, we identified that FLT3-ITD-positive patients with low p16INK4a expression have significantly worse prognoses. Consistent with these clinical findings, knockout of p16INK4a in mice was shown to accelerate FLT3-ITD AML onset. Mechanistic investigations further revealed that the FLT3-ITD mutation suppresses p16INK4a expression via the STAT5A-E2F3-EZH2 signaling axis. This downregulation of p16INK4a allows cells to evade senescence, thereby promoting increased malignancy and establishing a positive feedback loop that exacerbates disease progression. This mechanism provides a molecular explanation for the poorer long-term survival observed in this patient subset. Furthermore, the FLT3-ITD-STAT5A/E2F3/EZH2-p16INK4a axis identified in this study represents a promising therapeutic target for addressing refractory FLT3-ITD AML with low p16INK4a expression.
引用
- Zheng J, Jin L, Chen Y, et al. Targeting p16INK4a-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2025. PMID: 40841767. doi:10.1038/s41375-025-02743-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。